Education
About Us
Working with TipRanks
Follow Us
Abeona Therapeutics (ABEO)
NASDAQ:ABEO
ABEO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.05 - $8.45
Previous CloseN/A
Volume71.38K
Average Volume (3M)526.00K
Market Cap
$218.64M
Enterprise Value$179.23M
Total Cash (Recent Filing)$4.28M
Total Debt (Recent Filing)$5.50M
Price to Earnings (P/E)―
Beta0.58
Next Earnings
May 08, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.25
Shares Outstanding48,533,800
10 Day Avg. Volume754,013
30 Day Avg. Volume525,998
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)63.96
Price to Cash Flow (P/CF)-4.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.22
Forecast
1Y Price Target
$17.50Price Target Upside305.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Abeona Therapeutics News
PremiumCompany Announcements
Abeona Therapeutics: Positive Outlook Amid FDA Hopes
PremiumCompany Announcements
Abeona Therapeutics Reports 2024 Financial Results---
Bulls Say, Bears Say
Bulls Say
Commercialization PreparationAbeona is preparing for the commercialization of pz-cel by onboarding treatment centers, engaging payers, and educating stakeholders.
Patent ProtectionThe company has obtained additional patent protection for pz-cel, extending its use for the treatment of RDEB until June 2037 and its packaging and transport system until July 2040.
Regulatory ApprovalThe FDA has accepted Abeona's Biologics License Application for prademagene zamikeracel, with an approval decision date set for April 29, 2025.
Bears Say
Approval CompetitionThe efficacy and long-term durability of prademagene zamikeracel, along with the high list price of a competing product, should enable Abeona to outcompete Filsuvez in the RDEB population.
Market CompetitionThe efficacy and long-term durability of pz-cel should enable Abeona to readily outcompete Filsuvez in the RDEB population.
Regulatory ChallengesThe CRL for pz-cel only raised CMC-related issues, with no safety or efficacy concerns, boosting confidence in its resolution.
---
Ownership Overview
7.46% Insiders
5.48% Mutual Funds
50.61% Other Institutional Investors
30.90% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABEO FAQ
What was Abeona Therapeutics’s price range in the past 12 months?
Abeona Therapeutics lowest stock price was $3.05 and its highest was $8.45 in the past 12 months.
What is Abeona Therapeutics’s market cap?
Abeona Therapeutics’s market cap is $218.64M.
When is Abeona Therapeutics’s upcoming earnings report date?
Abeona Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 28 days.
How were Abeona Therapeutics’s earnings last quarter?
Abeona Therapeutics released its earnings results on Mar 20, 2025. The company reported $0.5 earnings per share for the quarter, beating the consensus estimate of -$0.348 by $0.848.
Is Abeona Therapeutics overvalued?
According to Wall Street analysts Abeona Therapeutics’s price is currently Undervalued.
Does Abeona Therapeutics pay dividends?
Abeona Therapeutics does not currently pay dividends.
What is Abeona Therapeutics’s EPS estimate?
Abeona Therapeutics’s EPS estimate is -0.37.
How many shares outstanding does Abeona Therapeutics have?
Abeona Therapeutics has 48,533,800 shares outstanding.
What happened to Abeona Therapeutics’s price movement after its last earnings report?
Abeona Therapeutics reported an EPS of $0.5 in its last earnings report, beating expectations of -$0.348. Following the earnings report the stock price went down -1.154%.
Which hedge fund is a major shareholder of Abeona Therapeutics?
Currently, no hedge funds are holding shares in ABEO
---
Abeona Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.50 (305.09% Upside)
$17.50 (305.09% Upside)
Blogger Sentiment
Bullish
ABEO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 386.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $41.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.8%
Last 30 Days ▲ 5.9%
Last 30 Days ▲ 5.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.55%
12-Months-Change
Fundamentals
Return on Equity
-216.57%
Trailing 12-Months
Asset Growth
70.20%
Trailing 12-Months
Company Description
Abeona Therapeutics
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
---
ABEO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reflects a generally positive outlook for Abeona Therapeutics, driven by anticipated FDA approvals and substantial revenue potential from pz-cel. The company is well-positioned with strong financial backing and manufacturing capabilities. However, the initial launch will be supply constrained, and general and administrative expenses have increased significantly due to launch preparations.Read More>---
ABEO Stock 12 Month Forecast
Average Price Target
$17.50
▲(305.09% Upside)
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Sorrento Therapeutics
―
uniQure
―
Brainstorm Cell Therapeutics
―
Adaptimmune Therapeutics
―
Best Analysts Covering ABEO
1 Year
1 Year Success Rate
1/3 ratings generated profit
1 Year Average Return
+0.13%
reiterated a buy rating 21 days ago
Copying James Molloy's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +0.13% per trade.
---